Press Release

Genospectra Appoints George E. Bers Executive Vice Preisdent, Commerical Operaions

Fremont, Calif., 7 September, 2005â??Genospectra, Inc., developer of innovative products and technologies for parallel quantitative biology (PQB), and the exclusive provider of QuantiGene and QuantiGene Plex quantitative gene expression profiling technology, today announced the appointment of George Bers to a newly created role, Executive Vice President, Commercial Operations.

â??We are pleased to call upon Georgeâ??s experience and expertise in the life sciences tools industry as we look for him to drive Genospectraâ??s commercial activities to the next level. George has earned an excellent reputation for leadership and business growth and we are enthusiastic about the contributions he will make as we continue to build Genospectra,â?? said Andy Schwab, Genospectra board member and Managing Partner at 5AM Ventures, a life sciences venture capital firm.

In his new role, Mr. Bers will be responsible for overseeing the Companyâ??s sales, marketing and business development activities. Highly regarded as an experienced leader, Mr. Bers is also expected to be an important contributor to Genospectraâ??s growth strategy. Mr. Bers has 30 years of experience in life sciences, drug discovery and clinical diagnostic product development, including proteomics, genomics, and cellular analysis. He has held various senior executive management positions at NuGEN, Beckman Coulter, Nanogen, and Bio-Rad Laboratories. Mr. Bers has a B.A. degree from Duke University, and a M.S. degree in Biochemistry from Georgetown University.

â??Genospectra has established a strong track record for revenue growth, initially based on QuantiGene products and now extended with our new QuantiGene Plex multiplexed RNA profiling on beads, new controllable RNAi technology, and cellular delivery products,â?? noted Dr. Frank Witney, Genospectra CEO. â??With this accelerated market presence and broader product diversity, we can now leverage the skills of a seasoned executive to manage all our commercial activities.â??

Commenting on his new role, George Bers added, â??Owing to its focus on the exciting new field of quantitative biology, an impressive product and intellectual property portfolio, and a great management team, Genospectra has an unusually bright future. I am delighted to be joining the company.â??

Genospectra

Genospectra is a privately-held life science company focused on parallel quantitative biology (PQB) to develop novel cell-based assays and tools that enable the multiplex measurement of molecular events, such as intracellular pathway analysis, in a quantitative and scalable manner. Genospectra has grown rapidly on the merits of QuantiGene and QuantiGene Plex, flagship product lines powered by the proprietary bDNA technology for gene expression analysis in cell-based assays. The company recently launched Express-si, a new siRNA delivery reagent for non-cytotoxic transfection into primary cell lines. Genospectra was founded in 2000 and is based in Fremont, CA. For further information, log on to www.genospectra.com.